Aura Biosciences (AURA) CTO receives new stock option and RSU awards

Rhea-AI Filing Summary

Aura Biosciences Chief Technology Officer Mark Plavsic reported equity grants. He acquired a stock option covering 112,661 shares and 62,339 shares of common stock through a restricted stock unit award.

The RSUs vest in four equal annual installments beginning on January 15, 2027. The option vests 25% on February 1, 2027, with the remaining shares vesting pro rata in 36 monthly installments, in each case contingent on his continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plavsic Mark

(Last) (First) (Middle)

C/O AURA BIOSCIENCES, INC.

80 GUEST STREET

(Street)

BOSTON MA 02135

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		62,339(1)	A	$0	243,736	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.14	03/02/2026		A		112,661		(2)	03/02/2036	Common Stock	112,661	$0	112,661	D

Explanation of Responses:

1. These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.

2. The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

	/s/ Conor Kilroy, as Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Aura Biosciences (AURA) report for Mark Plavsic?

Aura Biosciences reported that Chief Technology Officer Mark Plavsic received equity awards. He acquired 112,661 shares through a stock option grant and 62,339 shares via a restricted stock unit award, both subject to future vesting based on continued service with the company.

What type of equity awards did AURA grant to its Chief Technology Officer?

The Chief Technology Officer received a stock option and a restricted stock unit (RSU) award. The option covers 112,661 shares of common stock, while the RSU award represents 62,339 shares, each RSU corresponding to one share of Aura Biosciences common stock upon vesting.

How do the RSUs granted to Aura Biosciences CTO vest?

The restricted stock units vest in four substantially equal annual installments. Vesting begins on January 15, 2027, with additional installments each following year, and each vesting date requires Mark Plavsic to remain in service with Aura Biosciences through that date.

What is the vesting schedule for the stock options granted by Aura Biosciences?

The stock options vest 25% on February 1, 2027, with the remaining 75% vesting pro rata over 36 monthly installments afterward. Each monthly vesting date is conditioned on the Chief Technology Officer’s continued service with Aura Biosciences at that time.

Does this Aura Biosciences Form 4 reflect a stock purchase or an award?

The Form 4 reflects equity awards rather than an open-market stock purchase. Both the 112,661-share option and 62,339-share RSU grant are classified as grants or awards, with no cash purchase reported and vesting tied to the executive’s future service.

How many Aura Biosciences shares does Mark Plavsic hold after these transactions?

Following the reported transactions, Mark Plavsic directly holds 243,736 shares of Aura Biosciences common stock. This total includes the newly acquired 62,339 restricted stock units, which convert into shares of common stock as they vest over the specified schedule.